Abivax's 15-Minute Chart Hits RSI Oversold, KDJ Golden Cross Trigger

The 15-minute chart for Abivax has exhibited an oversold RSI and a KDJ Golden Cross at 10:45 AM on 20th October 2025. This indicates that the stock price has fallen precipitously and is now below its fundamental support level, while the momentum of the stock price is beginning to shift towards an upward trend. Consequently, there is potential for further increases in the stock price.

The 15-minute chart for Abivax (NASDAQ:ABVX) exhibited an oversold RSI and a KDJ Golden Cross at 10:45 AM on October 20, 2025. This technical indicator suggests that the stock price has fallen significantly and is now below its fundamental support level, while the momentum of the stock price is beginning to shift towards an upward trend. Consequently, there is potential for further increases in the stock price.

Analysts from Barclays and Guggenheim have recently initiated coverage on Abivax, with both firms assigning Overweight and Buy ratings, respectively. Barclays initiated coverage on October 13, assigning an Overweight rating with a $142 price target, while Guggenheim reiterated its Buy rating with a $150 price target on October 10. These ratings suggest that analysts believe Abivax is undervalued and has significant upside potential, according to a Barclays report.

Abivax is a clinical-stage biotechnology company developing antiviral compounds and therapeutic vaccines for severe infectious diseases. The company's recent developments, such as positive 8-week induction data in ulcerative colitis and positive Phase 3 trial results for obefazimod, have driven a significant rally in the stock price, with a 1,577% increase over the past six months, as reported by Investing.com.

Despite the recent sell-off, analysts remain optimistic about Abivax's potential. Barclays believes the stock remains undervalued based on the opportunity for a first-in-class oral molecule with biologic-like clinical efficacy in ulcerative colitis and Crohn's disease. The firm sees additional upside potential from Abivax's miR-124 mechanism, with positive maintenance data in ulcerative colitis and top-line results in Crohn's disease anticipated in the second half of 2026, as noted in the Investing.com coverage.

In summary, while Abivax's stock price has fallen significantly, technical indicators suggest a potential upward trend. Analysts from Barclays and Guggenheim remain optimistic about the company's prospects, assigning Overweight and Buy ratings, respectively. The recent developments in Abivax's pipeline and positive clinical trial results provide a strong foundation for further growth.